Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 17, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN)
shareholders approve all Board of Directors' proposals at this year's Ordinary
General Meeting.
Today the shareholders of Basilea approved the annual report, the financial
statements and consolidated financial statements for the business year 2011, and
discharged the members of the Board of Directors and Management. Shareholders
also approved carrying forward the accumulated deficit.
Mr. Hans-Beat Gürtler and Prof. Daniel Lew were re-elected to the Board of
Directors for a term of three years each.
Shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory Auditors
for the audit of the stand-alone and the consolidated financial statements for
the business year 2012.
The Board of Directors confirmed Mr. Werner Henrich as Chairman of the Board of
Directors and Mr. Hans-Beat Gürtler as Vice-Chairman.
At the Ordinary General Meeting for the financial year 2011, 53% of the total
share capital of the company were represented.
In his presentation to shareholders, Dr. Anthony Man, Chief Executive Officer,
commented: "Over the last year Basilea has built the foundation for two
potential regulatory filings. We now have topline data from our large U.S. phase
III HANDEL trial with oral alitretinoin that forms the basis of a potential
future U.S. filing and our partnership discussions. For ceftobiprole, targeted
for treatment of severe pneumonia in the hospital, we are moving forward with
our European marketing application planned for the second half of the year 2012
and are actively discussing potential partnerships for this drug addressing
resistant bacterial infections. We continue to advance the phase III program of
isavuconazole in addition to our two innovative phase I compounds. We are
focused on achieving clinical and regulatory milestones for our key clinical
value drivers, optimizing the value of our assets through potential
partnerships, and steadily increasing sales in Toctino."
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Through the fully integrated research and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. the company focuses on innovative pharmaceutical products in
the therapeutic areas of bacterial infections, fungal infections, oncology and
skin diseases, targeting the medical challenge of rising resistance and non-
response to current treatment options in the hospital and specialty care
setting. The Basilea group includes affiliates in European countries as well as
in China.
Basilea is currently marketing Toctino® (oral alitretinoin), approved in
European countries, Canada and Israel for the treatment of adults with severe
chronic hand eczema unresponsive to potent topical corticosteroids, in Denmark,
Finland, France, Germany, Iceland, Norway, Switzerland and the United Kingdom
and has appointed distributors for Toctino® in other selected European markets,
Canada, Israel, Mexico and the Republic of Korea. In the U.S., oral alitretinoin
is an investigational drug. Topline data from the U.S. phase III study (HANDEL)
on oral alitretinoin have been recently reported. The results are consistent
with previous randomized international studies.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal infections, the
company has entered into a license, co-development and co-promotion agreement
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both Gram-
positive bacteria, including MRSA, and many clinically important Gram-negative
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel investigational antibiotic for the treatment of
resistant Gram-negative infections, and the oncology drug candidate BAL101553
for the treatment of drug-resistant cancers are in phase I clinical testing.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future, anticipated results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, Ph.D. | Barbara Zink, Ph.D., MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
Press release (PDF):
http://hugin.info/134390/R/1603415/506913.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1603415]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Globex Posts Preliminary Economic Assessment on SEDARDatum: 17.04.2012 - 19:49 Uhr
Sprache: Deutsch
News-ID 136077
Anzahl Zeichen: 7140
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
